Exclusive: Weight loss startup Yazen raises €50m led by Verdane
THE SO WHAT
Consumer health is still one of the few categories where narrative plus outcomes can justify late-stage checks. If you’re building in digital health, assume investors will demand either clear reimbursement pathways or subscription economics that look more like SaaS than coaching.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureBending Spoons CEO on why M&A fails
The failure mode in most acquihires and rollups is integration discipline, not deal logic. If you’re buying product or talent this cycle, over-allocate leadership time to post-close operating cadence and under-allocate to pre-close pitch theater.
Startups & VentureWhy Investors Are Skeptical Over Australian Data Center Company Firmus's IPO
A polarizing IPO for an Nvidia-backed data center builder shows public markets are starting to separate “AI infra beta” from real contracted demand. If you’re raising for infra-heavy AI plays, expect sharper questions on utilization, power contracts, and tenant concentration — not just logo slides and Nvidia proximity.
Startups & VentureAlphabet’s Isomorphic Labs in Funding Talks for at Least $40 Billion Value
A $40B valuation for an AI-native drug discovery shop makes clear that pharma plus models is being priced as its own category, not just a tool vendor. Biotech and pharma operators should assume that access to proprietary model pipelines and data-sharing partnerships becomes a strategic weapon, not a back-office efficiency play.
Startups & VentureMalaysian Chip Firm SQAI Said to Plan $73 Million IPO in Early 2027
A RM300M (~$73M) IPO for a Malaysian advanced interconnect player is another data point that packaging and back-end are where smaller regional firms can still list and grow. If you're capacity-constrained on advanced packaging, start mapping Southeast Asian suppliers now—access may tighten post-IPO.